Acrivon Therapeutics’ shares climb 14% on plans to present cancer-test data
Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.
—————
Boost Internet Speed–
Free Business Hosting–
Free Email Account–
Dropcatch–
Free Secure Email–
Secure Email–
Cheap VOIP Calls–
Free Hosting–
Boost Inflight Wifi–
Premium Domains–
Free Domains